Form 8-K

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FC9CedtekoyK0OIaJ8wozlh9Edlno08W5x0WDgTnSTKLUVIV8yf+xfKlG9WEK+BV nSQEF+oNVPX3t6MhRNoDJQ== 0001193125-07-241834.txt : 20071109 0001193125-07-241834.hdr.sgml : 20071109 20071109121716 ACCESSION NUMBER: 0001193125-07-241834 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20071107 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20071109 DATE AS OF CHANGE: 20071109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NABI BIOPHARMACEUTICALS CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1225 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-04829 FILM NUMBER: 071229474 BUSINESS ADDRESS: STREET 1: 5800 PARK OF COMMERCE BLVD N W STREET 2: STE 322 CITY: BOCA RATON STATE: FL ZIP: 33487 BUSINESS PHONE: 5619895800 MAIL ADDRESS: STREET 1: 5800 PARK OF COMMERCE BLVD NW STREET 2: STE 322 CITY: BOCA RATON STATE: FL ZIP: 33487 FORMER COMPANY: FORMER CONFORMED NAME: NABI /DE/ DATE OF NAME CHANGE: 19960405 FORMER COMPANY: FORMER CONFORMED NAME: NORTH AMERICAN BIOLOGICALS INC DATE OF NAME CHANGE: 19920703 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 7, 2007

Nabi Biopharmaceuticals

(Exact name of registrant as specified in its charter)

Delaware

000-04829

59-1212264

State or other jurisdiction

of incorporation

Commission File Number

IRS Employer

Identification No.

5800 Park of Commerce Boulevard N.W., Boca Raton, FL 33487

(Address of principal executive offices) (Zip code)

(561) 989-5800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Nabi Biopharmaceuticals

Item 7.01. Regulation FD Disclosure

On the Company’s previously scheduled third quarter financial results conference call held on November 8, 2007, the Company discussed the results of its recently completed Phase IIb proof-of-concept study for NicVAX^® (Nicotine Conjugate Vaccine). A press release issued by the Company on November 7, 2007 discussing the results of this study is furnished as Exhibit 99.1 to this Report. On the conference call, the Company reviewed the webcast slides furnished as Exhibit 99.2 and referenced the Study Results Slides posted on the Company’s website and furnished as Exhibit 99.3.

The information in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, and it shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. Furthermore, the furnishing of the information included in this Item 7.01 is not intended to constitute a determination by the registrant that the information is material or that the dissemination of the information is required by Regulation FD.

Item 9.01. Item 9.01. Financial Statements and Exhibits


Exhibit number		Description
99.1		NicVAX Press Release

99.2		Webcast Slides

99.3		Study Results Slides

The information included in the exhibits to this Current Report on Form 8-K is furnished pursuant to Items 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. Furthermore, the furnishing of the information included in these exhibits to this Report is not intended to constitute a determination by the registrant that the information is material or that the dissemination of the information is required by Regulation FD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Nabi Biopharmaceuticals

Date: November 9, 2007	By:	/s/ Jordan I. Siegel
		Jordan I. Siegel
		Senior Vice President, Finance and Administration
		Chief Financial Officer and Treasurer

Index of Exhibits


Exhibit number		Description
99.1		NicVAX Press Release

99.2		Webcast Slides

99.3		Study Results Slides

EX-99.1 2 dex991.htm NICVAX PRESS RELEASE NicVAX Press Release

EXHIBIT 99.1


		NEWS RELEASE

Investor Relations 301-770-3099 \| www.nabi.com

FOR IMMEDIATE RELEASE

Nabi Biopharmaceuticals Announces Successful Completion of NicVAX® Phase 2b Trial;

Drug Shows Statistically Significant Rates of Smoking Cessation

and Continuous Long-Term Smoking Abstinence at 12 Months

Data Presented Today at the American Heart Association Scientific Sessions 2007 in Orlando, Florida

Boca Raton, Florida, November 7, 2007 – Nabi Biopharmaceuticals (NASDAQ: NABI) today announced the successful completion of its Phase 2b trial of NicVAX® (Nicotine Conjugate Vaccine), the company’s innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. The final 12-month data confirm the highly significant trends seen in the previous data at six and nine months for both smoking cessation and long-term smoking abstinence. These data were presented at 9:45 a.m., EST today at the American Heart Association (AHA) Scientific Sessions 2007 in Orlando, Florida by one of the trial’s lead investigators, Dr. Stephen Rennard, Larson Professor of Medicine, University of Nebraska Medical Center.

“I believe data from this trial are very encouraging – for smokers who are trying to quit as well as for the field of smoking cessation vaccines,” said Dr. Rennard. “Only a short time ago, it was difficult to find convincing evidence to link anti-nicotine antibody with smoking cessation. This double-blind, placebo-controlled trial has demonstrated a clinical proof of concept. The data show there is a correlation between antibody level and the ability of patients to quit smoking and remain abstinent over long periods of time. This development is key for the field of smoking cessation research and could have a significant impact on how we treat patients with nicotine addiction.”

NicVAX® Phase 2b Trial: Key Findings in Final 12 Month Data Set

Optimal NicVAX® Dose and Schedule Identified for Smoking Cessation and Long-Term Abstinence

A statistically significant number of patients treated with the NicVAX® optimal dose (400 micrograms) and schedule (Schedule 2) were able to quit smoking and remained abstinent over the long-term:

•

12-Month continuous abstinence: NicVAX® 400 micrograms, Schedule 2 = 16% (8/51), Placebo=6% (6/100), p<0.038 (intent to treat population)

•

12-Month continuous abstinence: NicVAX® 200 micrograms, Schedule 2 = 14% (7/50), Placebo=6% (6/100), p<0.056 (intent to treat population)

•

For the final 12-month data analysis, this response was calculated using total time after the Target Quit Date, rather than the general study week (which was used in interim data analyses). This conservative and stringent statistical approach yielded statistically significant findings even after a full year.

Anti-Nicotine Antibody Levels Drive Long-Term Smoking Abstinence

•

The rate of smoking cessation and ability to achieve long-term abstinence in treated patients was correlated with level of anti-nicotine antibodies at critical time points: The high antibody responder group (top 30% of antibody responders) showed continuous abstinence rates almost three times those of placebo at 12 months.

•

These high antibody responders continued to show statistically significant abstinence at 12 months:

•

NicVAX®= 16% (10/61) vs. Placebo= 6% (6/100), p<0.032

•

Subjects in the therapeutic effect window show a >30% likelihood of achieving at least four months of smoking abstinence and remaining entirely abstinent through 12 months following the first administration of NicVAX®.

Overall Health Benefit – High Antibody Responders Smoked Fewer Cigarettes

Those patients in the NicVAX® group who continued to smoke but who also showed a high antibody response (top third) showed a statistically significant reduction in cigarettes smoked over the full 12 months compared to placebo (p<0.022):

•

Using a repeated measures model, vaccinated smokers who failed to quit but showed a high antibody response smoked a median of only 10 cigarettes per day while in the study, compared to their own baseline values of 20 cigarettes per day before treatment.

Safety Trends Continue – NicVAX® Shows No Compensatory Smoking, No Increased Withdrawal

Importantly, there was no evidence of compensatory smoking or increase in withdrawal symptoms observed in NicVAX® patients at any stage of the 12-month trial. NicVAX® continued to be well-tolerated with the placebo and NicVAX® dose groups showing comparable adverse event profiles at each stage of the clinical study.

“We are excited and greatly encouraged by the significant learning which has come from this first efficacy trial of NicVAX.” said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi. “It is important to note that we have seen success in each of the critical parameters of this trial; we know the dimensions of the therapeutic antibody window which will drive continuous abstinence out to a full year, we know the relationship between the psychological and biochemical drives to quit and remain abstinent and, most importantly, we believe we now have the insight to drive a higher rate of response. We will use these encouraging final data to advance our NicVAX partnership discussions and to determine the optimal design for the next step in our clinical trial efforts for this important primary care product candidate.”

About the Phase 2b Study

The Phase 2b study was a double-blind, placebo-controlled and dose-ranging study comprised of 301 patients designed to establish proof of concept and the optimal dose for the Phase 3 program. This study was designed in collaboration with the U.S. Food and Drug Administration and other global regulatory agencies and incorporates the most current clinical trial standards and prevailing protocol design for smoking cessation studies. The trial’s primary endpoint is the rate of carbon monoxide (CO)-confirmed, continuous abstinence from smoking during weeks 19-26 after first vaccination. In May 2007, Nabi announced this trial’s six-month data, which showed that a statistically significant number of patients with in the high anti-nicotine antibody responder group met the trial’s primary endpoint of eight weeks of continuous abstinence between weeks 19-26.

About NicVAX®

NicVAX® is an innovative and proprietary investigational vaccine being developed by Nabi to treat nicotine addiction and prevent smoking relapse. NicVAX® is designed to stimulate the immune system to produce antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier. Therefore, NicVAX® blocks nicotine from reaching its receptors in the brain and prevents the highly-addictive pleasure sensation experienced by smokers and users of nicotine products. Pre-clinical and previous clinical data, as well as the study reported here, show that NicVAX®’s ability to block nicotine from reaching the brain could help people quit smoking. Because the body’s immune system can be boosted to produce long-lasting antibodies, Nabi believes NicVAX® also could be effective in preventing smoking relapse. Relapse is a significant challenge facing smokers and, with currently-available smoking cessation therapies, relapse rates can be as high as 90% in the first year after a smoker quits.

NicVAX® Development Progress to Date

In September 2005, Nabi announced that it received a $4.1 million grant from the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health. NIDA has also funded, in part, the costs for toxicology testing and earlier clinical trials in the U.S. and contributed scientific and clinical expertise to the program overall. In March 2006, Nabi Biopharmaceuticals announced that NicVAX® had received Fast Track Designation from the FDA, which facilitates the development of products that treat serious diseases where an unmet medical need exists. Nabi Biopharmaceuticals’ intellectual property portfolio for technology related to NicVAX® includes both issued and pending patents in the U.S. In addition, Nabi holds granted patents in 18 European countries, plus patents and pending patent applications in numerous other countries around the world.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and, in certain areas, market products that target serious medical conditions in the areas of hepatitis and transplants, gram positive bacterial infections and nicotine addiction. We are a vertically integrated company with sales of antibodies and other biologics, including Nabi-HB^® [Hepatitis B Immune Globulin (Human)], a pipeline of products in various stages of development and a state-of-the-art manufacturing capability. The company operates through two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics has responsibility for the company’s protein and immunological products and development pipeline, including Nabi-HB. Nabi Pharmaceuticals is responsible for the NicVAX® (Nicotine Conjugate Vaccine) and StaphVAX® (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. In September 2007, Nabi announced that it had entered into a definitive agreement with Biotest AG to sell the Nabi Biologics strategic business unit to Biotest Pharmaceuticals Corporation, including Nabi-HB® [Hepatitis B Immune Globulin (Human)], and other plasma business assets, including Nabi’s state-of-the-art plasma protein production plant, and nine FDA-certified plasma collection centers across the U.S. The acquisition also will include certain of Nabi’s Corporate Shared Services group assets and the company’s Boca Raton, Florida headquarters and other facilities, as well as the assumption of certain liabilities. This transaction is expected to close by the end of the year. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site:http://www.nabi.com.

Forward-Looking Statements

Statements in this release that are not strictly historical are forward-looking statements and include statements about the closing of the sale of Nabi Biologics and clinical trials and studies. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to: successfully close the sale of the Nabi Biologics SBU to Biotest AG; successfully partner with third parties to fund, develop, manufacture and/or distribute our existing and pipeline products, including NicVAX® and our Gram-positive infections products; obtain successful clinical trial results; our ability to successfully complete our strategic alternatives process; generate sufficient cash flow from sales of products or from milestone or royalty payments to fund our development and commercialization activities; attract and maintain the human and financial resources to commercialize current products and bring to market products in development; depend upon third parties to manufacture or fill our products; achieve approval and market acceptance of our products; expand our sales and marketing capabilities or enter into and maintain arrangements with third parties to market and sell our products; effectively and/or profitability use, or utilize the full capacity of, our vaccine manufacturing facility; manufacture NicVAX® or other products in our own vaccine manufacturing facility; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and our Quarterly Report for the quarters ended June 30, 2007 and March 31, 2007 on Form 10-Q with the Securities and Exchange Commission.

EX-99.2 3 dex992.htm WEBCAST SLIDES Webcast Slides

NicVAX™

Nicotine Conjugate Vaccine

Relationship of Anti-Nicotine

Antibody Levels to Abstinence:

Final Phase 2b Trial Results at 12 Months

November 8, 2007

Exhibit 99.2

Forward Looking Statements

Certain matters Nabi will discuss today consist of forward-looking statements

made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 relating to, among other things, Nabi’s

expectations concerning the company’s commercial and regulatory strategy

and business and financial outlook. These forward-looking statements are

not guarantees of future performance and are subject to a variety of risks and

uncertainties that could cause actual results to differ materially from the

results contemplated thereby. Any forward-looking statements made by Nabi

should be considered in light of the risks and uncertainties contained in our

filings with the Securities and Exchange Commission. Many of these factors

are

fully

discussed,

are

other

factors,

the

company's

Annual

Report on Form 10-K for the fiscal year ended December 31, 2006 and

Quarterly Reports on Form 10-Q with the Securities and Exchange

Commission. You are cautioned not to place undue reliance on these

forward-looking statements, which speak only as of today. Nabi undertakes

no obligation to update or revise the information provided herein, whether as

the

result

new

information,

future

events

circumstances

otherwise.

NicVAX Phase 2b Trial Design

Multi-center, randomized, double-blind, placebo

controlled study in smokers who want to quit smoking

—

Primary endpoint at 6-months: 8 weeks continuous abstinence in

antibody-stratified population

301 heavy smokers

—

Average of 24 cigarettes per day; no smoker less than 15 per day

2 doses (400 µg and 200 µg) vs. placebo

2 schedules for each dose:

—

Schedule 1: 4 injections over 6 months

—

Schedule 2: 5 injections over 6 months

Point prevalence and continuous abstinence rates

—

At 6 and 12 months

Primary and Secondary

Abstinence Measures

Target Quit Date

8 week

abstinence

immediately

prior to 6

months

Continuous abstinence to 6 months

Months

Primary End Point

Continuous abstinence to 12 months

Secondary End Point

12-Month Continuous Abstinence

14%

(n=7/50)

p=0.056

16%

(n=8/51)

p=0.038

Schedule 2

(n=3/50)

p=0.88

NicVAX

200 µg

(n=6/100)

Placebo

(n=3/50)

p=0.96

NicVAX

400 µg

Schedule 1

Antibody Response by Treatment Arm

Study Week

200 µg/Schedule 1

400 µg/Schedule 1

200 µg/Schedule 2

400 µg/Schedule 2

Exceeding the Effect Threshold Drives

Greater Abstinence

Intent to Treat Population

(n=6/98)

11%

(n=2/19)

p=0.37

22%

(n=6/27)

p=0.011

12-Month

Continuous

Abstinence Rates

NicVAX 400 µg

Below Threshold

TQD

Placebo

NicVAX 400 µg

Above Threshold

TQD

Schedule 2

Antibody Level Also Drives Late Quit

10%

15%

20%

25%

30%

35%

40%

Weeks following TQD

Top 33%

Bottom 67%

Placebo

Antibody Level Drives Decrease in Cigarette

Consumption in Non-Abstainers

Study Week

Placebo

Top 33%

Bottom 67%

Conclusions

Optimal dose and schedule drives efficacy

—

400 µg/ml, Schedule 2: best regimen to attain threshold antibody

response at target quit date (TQD)

—

Critical for quit rate and to achieve long term abstinence

High antibody levels drive long-term abstinence

—

Continued

high antibody levels sustain TQD-induced abstinence and

elicit additional spontaneous abstinence of four months or greater

duration

High antibody levels decrease cigarette consumption

—

In continuing smokers, high anti-nicotine antibody levels significantly

reduce cigarette consumption on a long term basis

Trial provides critical insights:

—

Antibody concentration and duration correlate with size of abstinent

population

—

Findings inform clinical development program moving forward

EX-99.3 4 dex993.htm STUDY RESULTS SLIDES Study Results Slides

A Randomized Placebo-Controlled

Trial of a Conjugate Nicotine Vaccine

(NicVAX

)

in Smokers Who Want to

Quit: 12 Month Results

Stephen Rennard, Douglas Jorenby, David

Gonzales, Nancy Rigotti, Arjen

de Vos, Enoch

Bortey, Roxanne Akhavain, Dorothy Hatsukami

U. Nebraska, U. Wisconsin, Oregon Health & Sciences U.,

Massachusetts General Hospital, Nabi Biopharmaceuticals,

and

U. Minnesota

Supported by a grant from the National Institute on Drug Abuse

Exhibit 99.3